Skip to Main Content

An official website of the United States government

Request for access to the Ovarian Biomarkers data in order to correlate values with those obtained on our multiplex platform

Principal Investigator
Name
Amy Skubitz
Degrees
Ph.D.
Institution
University of Minnesota
Position Title
Professor
Email
About this CDAS Project
Study
PLCO (Learn more about this study)
Project ID
PLCO-254
Initial CDAS Request Approval
Jan 20, 2017
Title
Request for access to the Ovarian Biomarkers data in order to correlate values with those obtained on our multiplex platform
Summary
This request is for access to the Ovarian Biomarkers data which includes 36 analytes for 119 cases and 952 matched controls. Our reason for requesting this data is so that we can compare these values with ones that we plan to generate using Proseek® Multiplex technology on the same PLCO serum samples. We will use the latest cutting-edge technology offered in the University of Minnesota Genomics Center by OLink Bioscience, the Proseek® Multiplex Oncology and Inflammation plates, in which 92 cancer-related protein biomarkers (including CA125 and HE4) and 92 inflammation-related proteins are simultaneously quantified based on the Proximity Extension Assay. This innovative technology combines the sensitivity of the polymerase chain reaction with the specificity of antibody-based detection methods, allowing multiplex biomarker detection and high throughput quantification. In this project, we are planning to analyze serum samples from the PLCO Screening Trial to validate our preliminary findings and develop a clinical test that can detect early stages of ovarian cancer.
Aims

Our long term goal is to develop a clinical blood test that can be used to detect early stages of ovarian cancer in the general population. One aim of this project is to analyze serum samples from the PLCO Screening Trial in order to validate the set of protein biomarkers that we found to be present in the sera of women with early stages of ovarian cancer. The clinical data that is linked to each patient’s serum sample will allow us to identify protein biomarkers that may be specific to the stage, grade, and pathological subtype of ovarian cancer. In addition, we will be able to control for age, race, ethnicity, family medical history, and many other variables. Our request for access to the Ovarian Biomarkers data which includes 36 analytes for 119 cases and 952 matched controls is based on our second aim of this project. Namely, we plan to compare the protein concentration values that we obtain from the Proseek® Multiplex plates to values that have been published in other studies that have used these same PLCO serum samples. Using the Proseek® Multiplex plates and our mathematical algorithm, we will determine whether we can detect which women have early stages of ovarian cancer prior to any symptomatic signs and prior to the elevation of their serum levels of CA125 as determined by ELISAs.

Collaborators

Joseph S. Koopmeiners
Kristin L.M. Boylan
Qing Cao